Women's Hospital School Of Medicine Zhejiang University
Phase
Phase 2
Started
2025-03-10
Last updated
2025-12-18
Condition(s) studied
Cervical CancerImmunochemotherapy
Investigational drug(s) / intervention(s)
Camrelizumab combined with chemotherapy
Camrelizumab combined with chemotherapy: Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Study summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1
Exclusion Criteria:
1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
5. Previous treatment with immune checkpoint inhibitors.
Primary outcome measure(s)
3-year disease-free survival rate — from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months
Trial sites (1)
Facility
City
Region
Status
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou
Zhejiang
Recruiting
More Women's Hospital School Of Medicine Zhejiang University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.